This article has multiple issues. Please helpimprove it or discuss these issues on thetalk page.(Learn how and when to remove these messages) (Learn how and when to remove this message)Needs more citations. Includes a large table which needs to be turned into prose or removed. |
| Muscarinic acetylcholine receptor antagonist | |
|---|---|
| Drug class | |
Skeletal formula ofscopolamine, a nonselective antagonist of the muscarinic receptors | |
| Class identifiers | |
| Synonyms | Muscarinic acetylcholine receptor antagonist; Antimuscarinic; Anti-muscarinic; mACh antagonist; mAChR antagonist; Muscarinic antagonist; Antimuscarinic agent; Antimuscarinic drug; Antimuscarinic medication |
| Use | Allergies,asthma,atrial fibrillation withbradycardia,[1]motion sickness,Parkinson's disease, etc. |
| ATC code | V |
| Biological target | Muscarinic acetylcholine receptors |
| External links | |
| MeSH | D018727 |
| Legal status | |
| In Wikidata | |
Amuscarinic acetylcholine receptor antagonist, also simply known as amuscarinic antagonist or as anantimuscarinic agent, is a type ofanticholinergicdrug that blocks the activity of themuscarinic acetylcholine receptors (mAChRs). The muscarinic receptors are proteins involved in the transmission of signals through certain parts of the nervous system, and muscarinic receptor antagonists work to prevent this transmission from occurring. Notably, muscarinic antagonists reduce the activation of theparasympathetic nervous system. The normal function of the parasympathetic system is often summarised as "rest-and-digest", and includes slowing of the heart, an increased rate of digestion,narrowing of the airways, promotion of urination, and sexual arousal. Muscarinic antagonists counter this parasympathetic "rest-and-digest" response, and also work elsewhere in both thecentral andperipheral nervous systems.
Drugs with muscarinic antagonist activity are widely used in medicine, in the treatment oflow heart rate,overactive bladder, respiratory problems such asasthma andchronic obstructive pulmonary disease (COPD). A number of other drugs, such asantipsychotics and thetricyclic family of antidepressants, have incidental muscarinic antagonist activity which can cause unwanted side effects such asdifficulty urinating, dry mouth and skin, andconstipation.
Acetylcholine (often abbreviatedACh) is a neurotransmitter whose receptors are proteins found insynapses and other cell membranes. Besides responding to their primary neurochemical, neurotransmitter receptors can be sensitive to a variety of other molecules. Acetylcholine receptors are classified into two groups based on this:
Most muscarinic receptor antagonists are synthetic chemicals; however, the two most commonly used anticholinergics,scopolamine andatropine, arebelladonna alkaloids, and are naturally extracted from plants such asAtropa belladonna, commonly known asdeadly nightshade. The name "belladonna", Italian for "beautiful woman", is thought to derive from one of the antimuscarinic effects of these alkaloids, having been put into use by women for the cosmetic purpose of promoting dilation of thepupils.[2]
Muscarinic antagonist effects andmuscarinic agonist effects counterbalance each other forhomeostasis.
Certain muscarinic antagonists can be classified into either long-acting muscarinic receptor antagonists (LAMAs) or short-acting muscarinic receptor antagonists (SAMAs), depending on when maximum effect occurs and for how long the effect persists.[3]
This sectionneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources in this section. Unsourced material may be challenged and removed. Find sources: "Muscarinic antagonist" – news ·newspapers ·books ·scholar ·JSTOR(March 2024) (Learn how and when to remove this message) |
Scopolamine andatropine have similar effects on theperipheral nervous system. However, scopolamine has greater effects on thecentral nervous system (CNS) than atropine due to its ability to cross theblood–brain barrier.[4] At higher-than-therapeutic doses, atropine and scopolamine cause CNS depression characterized by amnesia, fatigue, and reduction inrapid eye movement sleep. Scopolamine (Hyoscine) hasanti-emetic activity and is, therefore, used to treatmotion sickness.
Antimuscarinics are also used as anti-parkinsonian drugs. Inparkinsonism, there is imbalance between levels ofacetylcholine anddopamine in the brain, involving both increased levels of acetylcholine and degeneration ofdopaminergic pathways (nigrostriatal pathway). Thus, in parkinsonism there is decreased level of dopaminergic activity. One method of balancing the neurotransmitters is through blocking central cholinergic activity using muscarinic receptor antagonists.
Atropine acts on theM2 receptors of the heart and antagonizes the activity of acetylcholine. It causestachycardia by blocking vagal effects on thesinoatrial node. Acetylcholine hyperpolarizes the sinoatrial node; this is overcome by MRAs, and thus they increase the heart rate. If atropine is given by intramuscular or subcutaneous injection, it causes initialbradycardia. This is because when administered intramuscularly or subcutaneously atropine acts on presynapticM1 receptors (autoreceptors). Uptake of acetylcholine inaxoplasm is prevented and the presynaptic nerve releases more acetylcholine into thesynapse, which initially causes bradycardia.
In theatrioventricular node, theresting potential is lowered, which facilitates conduction. This is seen as a shortened PR-interval on anelectrocardiogram. It[clarification needed] has an opposite effect onblood pressure. Tachycardia and stimulation of thevasomotor center causes an increase in blood pressure. But, due to feedback regulation of the vasomotor center, there is a fall in blood pressure due tovasodilation.
Important[5] muscarinic antagonists includeatropine,hyoscyamine,hyoscine butylbromide andhydrobromide,ipratropium,tropicamide,cyclopentolate,pirenzepine andscopolamine.
Muscarinic antagonists such asipratropium bromide can also be effective in treatingasthma, sinceacetylcholine is known to causesmooth muscle contraction, especially in thebronchi.
This sectionis inlist format but may read better asprose. You can help byconverting this section, if appropriate.Editing help is available.(March 2024) |
| Substance | Selectivity | Clinical use | Adverse effects | Notes | Trade names |
|---|---|---|---|---|---|
| Atropine (D/L-Hyoscyamine) | NS |
| CD[5] | Symax, HyoMax, Anaspaz, Egazil, Buwecon, Cystospaz, Levsin, Levbid, Levsinex, Donnamar, NuLev, Spacol T/S and Neoquess | |
| Atropine methonitrate | NS |
| Blocks transmission inganglia.[5] Lacks CNS effects[7] | ||
| Aclidinium bromide | Selective[clarification needed] |
| Long acting antagonist | Tudorza | |
| Benztropine | M1-selective |
| Reduces the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency. | Cogentin | |
| Cyclopentolate | NS |
|
| Short acting,CD[5] | |
| Diphenhydramine | NS |
|
| Acts in the central nervous system, blood vessels and smooth muscle tissues | Benadryl,Nytol |
| Doxylamine | NS |
|
| Unisom | |
| Dimenhydrinate | Combination of diphenhydramine with a methylxanthine salt | Dramamine, Gravol | |||
| Dicyclomine | Bentyl | ||||
| Darifenacin | Selective forM3[7] | Urinary incontinence[7] | Few side effects[7] | Enablex | |
| Flavoxate | Urispas | ||||
| Glycopyrrolate (Glycopyrronium bromide) | NS |
| Does not cross theblood–brain barrier and has few to no central effects.[9] | Robinul, Cuvposa, Seebri | |
| Hydroxyzine | Very mild/negligible action | Vistaril, Atarax | |||
| Ipratropium bromide | NS | Asthma andbronchitis[5] |
| Lacksmucociliary excretion inhibition.[5] | Atrovent and Apovent |
| Mebeverine |
|
| A muscolotropic spasmolytic with a strong and selective action on the smooth muscle spasm of the gastrointestinal tract, in particular of the colon. | Colofac, Duspatal, Duspatalin | |
| Oxybutynin | M1/3/4 selective | Ditropan | |||
| Pirenzepine | M1-selective[5] |
| (fewer than non-selective ones)[5] | Inhibitsgastric secretion[5] | |
| Procyclidine | NS |
| Overdose produces confusion, agitation and sleeplessness that can last up to or more than 24 hours. Pupils become dilated and unreactive to light. Tachycardia (fast heart beat), as well as auditory and visual hallucinations | ||
| Scopolamine (L-Hyoscine) | NS |
| CD[5] | Scopace, Transderm-Scop, Maldemar, Buscopan | |
| Solifenacin |
| Competitive antagonist | Vesicare | ||
| Tropicamide | NS |
|
| Short acting,CD[5] | |
| Tiotropium | Spiriva | ||||
| Trihexyphenidyl/Benzhexol | M1 selective | PD | Drug at relative dose has 83% activity of atropine, thus has the same side-effects | Artane | |
| Tolterodine | Detrusitol, Detrol |
Themuscarinic acetylcholine receptor subtypesectivities of a large number of antimuscarinic drugs have been reviewed.[10]
| Compound | M1 | M2 | M3 | M4 | M5 | Species | Ref |
|---|---|---|---|---|---|---|---|
| 3-Quinuclidinyl benzilate | 0.035–0.044 | 0.027–0.030 | 0.080–0.088 | 0.034–0.037 | 0.043–0.065 | Human | [11][12] |
| 4-DAMP | 0.57–0.58 | 3.80–7.3 | 0.37–0.52 | 0.72–1.17 | 0.55–1.05 | Human | [13][14] |
| AF-DX 250 | 427 | 55.0 | 692 | 162 | 3020 | Human | [13] |
| AF-DX 384 | 30.9 | 6.03 | 66.1 | 10.0 | 537 | Human | [13] |
| AQ-RA 741 | 28.8 | 4.27 | 63.1 | 6.46 | 832 | Human | [13] |
| Atropine | 0.21–0.50 | 0.76–1.5 | 0.15–1.1 | 0.13–0.6 | 0.21–1.7 | Human | [11][15][14] |
| Benzatropine (benztropine) | 0.231 | 1.4 | 1.1 | 1.1 | 2.8 | Human | [11] |
| Biperiden | 0.48 | 6.3 | 3.9 | 2.4 | 6.3 | Human | [11] |
| Darifenacin | 5.5–13 | 47–77 | 0.84–2.0 | 8.6–22 | 2.3–5.4 | Human | [14][16] |
| Dicycloverine (dicyclomine) | 57 (IC50) | 415 (IC50) | 67 (IC50) | 97 (IC50) | 53 (IC50) | Human/rat | [15] |
| Glycopyrrolate | 0.37 | 1.38 | 1.31 | 0.41 | 1.30 | Human | [9] |
| Hexahydrodifenidol | 11 | 200 | 16 | 76 (IC50) | 83 | Human/rat | [15] |
| Hexahydrosiladifenidol | 44 | 249 | 10 | 298 (IC50) | 63 | Human/rat | [15] |
| (R)-Hexbutinol | 2.09 | 20.9 | 2.14 | 3.02 | 5.50 | Human | [13] |
| Hexocyclium | 2.3 | 23 | 1.4 | 5.5 | 3.7 | Human/rat | [15] |
| Himbacine | 107 | 10.0 | 93.3 | 11.0 | 490 | Human | [13] |
| Ipratropium | 0.49 | 1.5 | 0.51 | 0.66 | 1.7 | Human | [16] |
| Methoctramine | 16–50 | 3.6–14.4 | 118–277 | 31.6–38.0 | 57–313 | Human | [15][13][17] |
| N-Methylscopolamine | 0.054–0.079 | 0.083–0.251 | 0.052–0.099 | 0.026–0.097 | 0.106–0.125 | Human | [13] |
| Orphenadrine | 48 | 213 | 120 | 170 | 129 | Human | [12] |
| Otenzepad (AF-DX 116) | 1300 | 186 | 838 | 1800 (IC50) | 2800 | Human/rat | [15] |
| Oxybutynin | 0.66 | 13 | 0.72 | 0.54 | 7.4 | Human | [14] |
| pFHHSiD | 22.4 | 132 | 15.5 | 31.6 | 93.3 | Human | [13] |
| Pirenzepine | 6.3–8 | 224–906 | 75–180 | 17–37 | 66–170 | Human | [11][15][13][14] |
| Procyclidine | 4.6 | 25 | 12.4 | 7 | 24 | Human | [11] |
| Propiverine | 476 | 2970 | 420 | 536 | 109 | Human | [14] |
| Scopolamine (hyoscine) | 1.1 | 2.0 | 0.44 | 0.8 | 2.07 | Human | [11] |
| Silahexacyclium | 2.0 | 35 | 1.2 | 3.2 | 2.0 | Human/rat | [15] |
| Timepidium | 34 | 7.7 | 31 | 18 | 11 | Human | [14] |
| Tiquizium | 4.1 | 4.0 | 2.8 | 3.6 | 8.2 | Human | [14] |
| Trihexyphenidyl | 1.6 | 7 | 6.4 | 2.6 | 15.9 | Human | [11] |
| Tripitamine (tripitramine) | 1.58 | 0.27 | 38.25 | 6.41 | 33.87 | Human | [17] |
| Zamifenacin | 55 | 153 | 10 | 68 | 34 | Human | [14] |
| Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. | |||||||
| Compound | M1 | M2 | M3 | M4 | M5 | Species | Ref |
|---|---|---|---|---|---|---|---|
| Brompheniramine | 25700 | 32400 | 50100 | 67600 | 28800 | Human | [18] |
| Chlorphenamine (chlorpheniramine) | 19000 | 17000 | 52500 | 77600 | 28200 | Human | [18] |
| Cyproheptadine | 12 | 7 | 12 | 8 | 11.8 | Human | [12] |
| Diphenhydramine | 80–100 | 120–490 | 84–229 | 53–112 | 30–260 | Human | [11][19] |
| Doxylamine | 490 | 2100 | 650 | 380 | 180 | Human | [19] |
| Mequitazine | 5.6 | 14 | 5.3 | 11.1 | 11.0 | Human | [12] |
| Terfenadine | 8710 | 8510 | 5250 | 30900 | 11200 | Human | [18] |
| Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. | |||||||
| Compound | M1 | M2 | M3 | M4 | M5 | Species | Ref |
|---|---|---|---|---|---|---|---|
| Amitriptyline | 14.7 | 11.8 | 12.8 | 7.2 | 15.7 | Human | [12] |
| Bupropion | >35,000 | >35,000 | >35,000 | >35,000 | >35,000 | Human | [12] |
| Citalopram | 1430 | ND | ND | ND | ND | Human | [20] |
| Desipramine | 110 | 540 | 210 | 160 | 143 | Human | [12] |
| Desmethylcitalopram | >10000 | >10000 | >10000 | >10000 | >10000 | Human | [21] |
| Desmethyldesipramine | 404 | 927 | 317 | 629 | 121 | Human | [21] |
| Desvenlafaxine | >10000 | >10000 | >10000 | >10000 | >10000 | Human | [22] |
| Dosulepin (dothiepin) | 18 | 109 | 38 | 61 | 92 | Human | [12] |
| Doxepin | 18–38 | 160–230 | 25–52 | 20–82 | 5.6–75 | Human | [19][12] |
| Escitalopram | 1242 | ND | ND | ND | ND | Human | [20] |
| Etoperidone | >35000 | >35000 | >35000 | >35000 | >35000 | Human | [12] |
| Femoxetine | 92 | 150 | 220 | 470 | 400 | Human | [12] |
| Fluoxetine | 702–1030 | 2700 | 1000 | 2900 | 2700 | Human | [12][20] |
| Fluvoxamine | 31200 | ND | ND | ND | ND | Human | [20] |
| Imipramine | 42 | 88 | 60 | 112 | 83 | Human | [12] |
| Lofepramine | 67 | 330 | 130 | 340 | 460 | Human | [12] |
| Norfluoxetine | 1200 | 4600 | 760 | 2600 | 2200 | Human | [12] |
| Nortriptyline | 40 | 110 | 50 | 84 | 97 | Human | [12] |
| Paroxetine | 72–300 | 340 | 80 | 320 | 650 | Human | [12][20] |
| Sertraline | 427–1300 | 2100 | 1300 | 1400 | 1900 | Human | [12][20] |
| Tianeptine | >10000 | >10000 | >10000 | >10000 | >10000 | Human | [23] |
| Trazodone | >35,000 | >35,000 | >35,000 | >35,000 | >35,000 | Human | [19][12] |
| Venlafaxine | >35000 | >35000 | >35000 | >35000 | >35000 | Human | [12] |
| Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. | |||||||
| Compound | M1 | M2 | M3 | M4 | M5 | Species | Ref |
|---|---|---|---|---|---|---|---|
| Amisulpride | >10,000 | >10,000 | >10,000 | >10,000 | >10,000 | Human | [24] |
| Aripiprazole | 6780 | 3510 | 4680 | 1520 | 2330 | Human | [25] |
| Asenapine | >10000 | >10000 | >10000 | >10000 | ND | Human | [26] |
| Bromperidol | 7600 | 1800 | 7140 | 1700 | 4800 | Human | [11] |
| Chlorprothixene | 11 | 28 | 22 | 18 | 25 | Human | [11] |
| Chlorpromazine | 25 | 150 | 67 | 40 | 42 | Human | [11] |
| Clozapine | 1.4–31 | 7–204 | 6–109 | 5–27 | 5–26 | Human | [11][26][27][28] |
| Cyamemazine (cyamepromazine) | 13 | 42 | 32 | 12 | 35 | Human | [29] |
| N-Desmethylclozapine | 67.6 | 414.5 | 95.7 | 169.9 | 35.4 | Human | [30] |
| Fluperlapine | 8.8 | 71 | 41 | 14 | 17 | Human | [11] |
| Fluphenazine | 1095 | 7163 | 1441 | 5321 | 357 | Human | [31] |
| Haloperidol | >10000 | >10000 | >10000 | >10000 | >10000 | Human | [26][27] |
| Iloperidone | 4898 | 3311 | >10000 | 8318 | >10000 | Human | [32] |
| Loxapine | 63.9–175 | 300–590 | 122–390 | 300–2232 | 91–241 | Human | [11][33] |
| Melperone | >15000 | 2400 | >15000 | 4400 | >15000 | Human | [11] |
| Mesoridazine | 10 | 15 | 90 | 19 | 60 | Human | [11] |
| Molindone | ND | ND | >10000 | ND | ND | Human | [34] |
| Olanzapine | 1.9–73 | 18–96 | 13–132 | 10–32 | 6–48 | Human | [26][27][28] |
| Perphenazine | ND | ND | 1848 | ND | ND | Human | [34] |
| Pimozide | ND | ND | 1955 | ND | ND | Human | [34] |
| Quetiapine | 120–135 | 630–705 | 225–1320 | 660–2990 | 2990 | Human | [26][27] |
| Remoxipride | >10000 | >10000 | >10000 | >10000 | ND | Human | [26] |
| Rilapine | 190 | 470 | 1400 | 1000 | 1100 | Human | [11] |
| Risperidone | 11000 | ≥3700 | 13000 | ≥2900 | >15000 | Human | [11][26] |
| Sertindole | ND | ND | 2692 | ND | ND | Human | [34] |
| Tenilapine | 260 | 62 | 530 | 430 | 660 | Human | [11] |
| Thioridazine | 2.7 | 14 | 15 | 9 | 13 | Human | [11] |
| Thiothixene | >10000 | >10000 | >10000 | >10000 | 5376 | Human | [35] |
| cis-Thiothixene | 2600 | 2100 | 1600 | 1540 | 4310 | Human | [11] |
| Tiospirone | 630 | 180 | 1290 | 480 | 3900 | Human | [11] |
| Trifluoperazine | ND | ND | 1001 | ND | ND | Human | [34] |
| Ziprasidone | ≥300 | >3000 | >1300 | >1600 | >1600 | Human | [27][36] |
| Zotepine | 18 | 140 | 73 | 77 | 260 | Human | [11] |
| Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. | |||||||
{{cite book}}: CS1 maint: location missing publisher (link)